Foresite Capital Management V’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Foresite Capital Management V’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-10,811,887	Closed	-$19.6M	–	10
2023 Q2	$19.6M	Buy	10,811,887 +773,952	+8%	+$1.42M	14.29%	3
2023 Q1	$13.3M	Hold	10,037,935	–	–	9.79%	3
2022 Q4	$17M	Buy	10,037,935 +637,420	+7%	+$808K	13.18%	5
2022 Q3	$17.4M	Hold	9,400,515	–	–	13.37%	4
2022 Q2	$28.9M	Hold	9,400,515	–	–	20.16%	1
2022 Q1	$67.9M	Hold	9,400,515	–	–	27.72%	1
2021 Q4	$154M	Buy	9,400,515 +8,798,015	+1,460%	+$102M	37.81%	1
2021 Q3	$6M	Hold	602,500	–	–	1.86%	13
2021 Q2	$6.01M	Hold	602,500	–	–	2.37%	13
2021 Q1	$6M	Buy	+602,500	New	+$6.23M	1.76%	12

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Foresite Capital Management V's PRDS Position: Q3 2023 in Review

Foresite Capital Management V sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 10,811,887 shares — an estimated $19.6M sold.

Foresite Capital Management V first reported a position in PRDS in Q1 2021 and held it in 10 quarters. The position peaked at $154M in Q4 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Foresite Capital Management V reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Foresite Capital Management V sold 10,811,887 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $19.6M.
Foresite Capital Management V first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Foresite Capital Management V's Pardes Biosciences, Inc. Common Stock position peaked at $154M in Q4 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Foresite Capital Management V's 13F filing for Q3 2023, filed 13 Nov 2023.